A 2021 study (Cai et al., Acta Pharm Sin B) established a cathepsin B-cleavable, Gd-DOTA-labeled branched glycopolymer-paclitaxel prodrug as a combined therapy-and-MR-imaging (theranostic) nanomedicine in a single 4T1 mouse breast-tumor model, with single-dose pharmacokinetics, biodistribution, and gadolinium-retention data in normal-renal-function mice. Whether this design is robust across tumors differing in cathepsin B expression level and cellular source, and whether its clearance and reduced-Gd-retention advantages survive repeated dosing and impaired renal function — the setting where gadolinium-induced fibrosis risk is concentrated — remain untested. The cross-tumor cathepsin B-expression dependence remains open at the field level, and no existing study has tested the platform's gadolinium biodistribution or retention after repeated dosing or under impaired renal function.

Background

Paclitaxel (PTX) is a microtubule-stabilizing antimitotic chemotherapeutic whose clinical use is limited by poor solubility and off-target toxicity. One established strategy is the polymeric prodrug: the drug is covalently attached to a macromolecular carrier through a linker that is cleaved only under conditions found in tumors, so that release is triggered at the disease site. Cathepsin B is a lysosomal cysteine protease overexpressed in many solid tumors and in tumor-associated stromal cells; the tetrapeptide GFLG is selectively cleaved by cathepsin B and serves as the standard enzyme-cleavable linker, already used in clinically approved antibody-drug conjugates of the vedotin type. For the diagnostic half of a theranostic, gadolinium (Gd)-based contrast agents shorten the T1 relaxation time in magnetic resonance imaging (MRI), but free Gd ions are toxic, so Gd is administered chelated (here by DOTA, a macrocyclic chelator); in patients with severe renal impairment, exposure to Gd-based contrast agents can cause nephrogenic systemic fibrosis (NSF), a debilitating fibrosing disorder, which is the reason long-term Gd retention is a central safety concern for macromolecular Gd agents.

Cai et al. (2021) constructed a branched glycopolymer (a synthetic glucose-bearing polymer of about 244 kDa) carrying PTX through GFLG linkers and Gd-DOTA units for MR imaging. The design intent is that cathepsin B in the tumor degrades the conjugate into small (about 28 kDa) renal-clearable fragments, releasing PTX while allowing the Gd to be excreted rather than retained. In a 4T1 mouse breast-tumor model the conjugate achieved 90.6% tumor-growth inhibition (versus 28.0% for free PTX), tumor accumulation of roughly 4.3% of the injected dose per gram of tissue at 24 h, a longitudinal relaxivity r1r_1 (the increase in the MRI water-signal recovery rate per unit Gd concentration) of 7.1 mM−1 s−1\mathrm{mM}^{-1}\,\mathrm{s}^{-1}, or 1.97 times that of Gd-DTPA, the clinically used small-molecule Gd contrast agent — and markedly reduced Gd retention at 96 h relative to the conjugate's own 24 h biodistribution (in liver, from 30.9% to 11.9% of the injected dose per gram; in spleen, from 18.4% to 6.1%), which the paper attributes to the macrocyclic DOTA chelator in mice with normal renal function. No direct 96 h conjugate-versus-Gd-DTPA retention comparison exists: the 96 h sacrifice for Gd-DTPA-treated mice was canceled because extremely low Gd concentrations were already detected at 24 h (about 0.1% ID/g in liver). However, the pharmacokinetic, biodistribution, Gd-retention, and MRI time-course measurements were single-dose studies in mice with normal renal function, and all efficacy and safety read-outs came from one tumor model. The paper itself notes that the reduced Gd retention was demonstrated in animals with normal renal function, leaving the renal-dysfunction setting untested. Whether the platform's triggering, imaging performance, efficacy, and degradation-clearance behavior depend on the level and cellular source (tumor versus stromal) of cathepsin B in the tumor, and whether the clearance and Gd-retention advantages persist under repeated dosing and impaired renal function — precisely where the NSF risk lives — remain undetermined.

Problem Statement

Determine the translational robustness of the cathepsin B-responsive, gadolinium-labeled branched glycopolymer-paclitaxel theranostic design beyond its single 4T1 breast-tumor demonstration, in two linked respects: (1) cathepsin B-expression dependence — establish whether cathepsin B-triggered PTX release, degradation of the conjugate into renal-clearable fragments, MRI contrast performance, and antitumor efficacy persist across tumor types that differ in cathepsin B expression level and in the cellular source of the enzyme (tumor cells versus stromal cells), or whether the design fails when expression is low or predominantly stromal; and (2) gadolinium safety under chronic and compromised-renal conditions — establish whether the biodistribution, clearance, and reduced-Gd-retention advantages observed after a single dose in normal-renal-function mice persist under a repeated dosing regimen and in settings of impaired renal function, where gadolinium deposition and gadolinium-induced fibrosis risk are concentrated. Together these two questions decide whether the enzyme-triggered, biodegradation-enabled Gd-clearance concept is a general design principle for cancer theranostics or an artifact of one favorable preclinical model.

References

  1. Cai H, Xiang Y, Zeng Y, Li Z, Zheng X, Luo Q, Zhu H, Gong Q, Gu Z, Liu Y, Zhang H, Luo K. Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment. Acta Pharmaceutica Sinica B 2021;11(2):544-559. doi:10.1016/j.apsb.2020.07.023. https://doi.org/10.1016/j.apsb.2020.07.023
  2. Guo C, Zeng Y, Ou Y, Gu Z, Luo K. Cathepsin B-Responsive Dendronized-Hyaluronic Acid Nanomedicine for Simultaneous Cancer Theranostics. MedComm - Oncology 2025;4(3):e70035. doi:10.1002/mog2.70035. https://doi.org/10.1002/mog2.70035
  3. Li H, Feng Y, Luo Q, Li Z, Li X, Gan H, Gu Z, Gong Q, Luo K. Stimuli-activatable nanomedicine meets cancer theranostics. Theranostics 2023;13(15):5386-5417. doi:10.7150/thno.87854. https://doi.org/10.7150/thno.87854
  4. Giri A, Shin Y, Ha J, Chae S, Shrestha P, Pham K-Y, Kwon TK, Park JH, Jeong J-H, Lee NK, Yook S. Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery. Journal of Controlled Release 2025;387:114197. doi:10.1016/j.jconrel.2025.114197. https://doi.org/10.1016/j.jconrel.2025.114197
  5. Huang C-H, Chang E, Zheng L, Raj JGJ, Wu W, Pisani LJ, Daldrup-Link HE. Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy. Theranostics 2023;13(6):1745-1758. doi:10.7150/thno.79342. https://doi.org/10.7150/thno.79342
  6. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annual Review of Medicine 2016;67:273-291. doi:10.1146/annurev-med-063014-124936. https://doi.org/10.1146/annurev-med-063014-124936
  7. Li H, Zeng Y, Zhang H, Gu Z, Gong Q, Luo K. Functional gadolinium-based nanoscale systems for cancer theranostics. Journal of Controlled Release 2021;329:482-512. doi:10.1016/j.jconrel.2020.08.064. https://doi.org/10.1016/j.jconrel.2020.08.064